Operating Lease, Right-of-Use Asset of BIOCRYST PHARMACEUTICALS INC from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
BIOCRYST PHARMACEUTICALS INC quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 30 Sep 2021 to 30 Sep 2025.
  • BIOCRYST PHARMACEUTICALS INC Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $7,725,000, a 7.3% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

BIOCRYST PHARMACEUTICALS INC Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $7,725,000 -$612,000 -7.3% 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $7,916,000 -$619,000 -7.3% 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $7,891,000 -$973,000 -11% 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $8,061,000 -$621,000 -7.2% 31 Dec 2024 10-Q 04 Nov 2025 2025 Q3
Q3 2024 $8,337,000 -$3,043,000 -27% 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $8,535,000 +$1,589,000 +23% 30 Jun 2024 10-Q 06 Aug 2024 2024 Q2
Q1 2024 $8,864,000 +$1,818,000 +26% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $8,682,000 +$4,440,000 +105% 31 Dec 2023 10-K 25 Feb 2025 2024 FY
Q3 2023 $11,380,000 +$4,583,000 +67% 30 Sep 2023 10-Q 08 Nov 2023 2023 Q3
Q2 2023 $6,946,000 30 Jun 2023 10-Q 07 Aug 2023 2023 Q2
Q1 2023 $7,046,000 31 Mar 2023 10-Q 08 May 2023 2023 Q1
Q4 2022 $4,242,000 -$2,230,000 -34% 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q3 2022 $6,797,000 +$1,606,000 +31% 30 Sep 2022 10-Q 04 Nov 2022 2022 Q3
Q4 2021 $6,472,000 31 Dec 2021 10-K 27 Feb 2023 2022 FY
Q3 2021 $5,191,000 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.